Department of Haematology, IUCT-Oncopole, CHU Toulouse, Toulouse, France.
Pharmacy Department IUCT (Institut Universitaire du Cancer) Oncopole, University Hospital Toulouse, Toulouse, France.
J Oncol Pharm Pract. 2021 Oct;27(7):1730-1735. doi: 10.1177/1078155220968615. Epub 2020 Oct 25.
Brentuximab vedotin (Bv) has been approved for the treatment of Refractory/Relapsed (R/R) Anaplastic Large Cell Lymphomas (ALCL) and cutaneous T-Cell Lymphomas, but is also effective in other CD30+ malignancies. We report here the outcomes of patients with various R/R Peripheral T Cell Lymphoma (PTCL) treated with Bv in real life practice.
This was a retrospective, single-center study based on medical records of patients with R/R PTCL treated either with Bv alone or in combination with chemotherapy.
Among 27 patients treated with Bv, neutropenia was the main serious adverse event observed in particular when Bv was used as combination treatment. The complete Response Rates (CRR) was 40.7%; it was significantly improved when Bv was used as combination treatment. The majority of eligible patients (7/10) underwent Stem Cell Transplantation. Median Progression Free Survival (PFS) and Overall Survival (OS) were 5.2 months and 12.5 months respectively.
Our current study shows that Bv used in combination with chemotherapy provides a high CRR and thereby allows SCT in R/R PTCL. The use of Bv treatments in this setting warrants further investigation.
本妥昔单抗贝凡珠单抗（Bv）已被批准用于治疗难治性/复发性（R/R）间变性大细胞淋巴瘤（ALCL）和皮肤 T 细胞淋巴瘤，但对其他 CD30+恶性肿瘤也有效。我们在此报告了在真实临床实践中使用 Bv 治疗各种 R/R 外周 T 细胞淋巴瘤（PTCL）患者的结果。
这是一项基于 R/R PTCL 患者接受 Bv 单药或联合化疗治疗的病历的回顾性、单中心研究。
在接受 Bv 治疗的 27 名患者中，中性粒细胞减少是主要的严重不良事件，尤其是当 Bv 作为联合治疗时。完全缓解率（CRR）为 40.7%；当 Bv 作为联合治疗时，CRR 显著提高。大多数符合条件的患者（7/10）接受了干细胞移植。中位无进展生存期（PFS）和总生存期（OS）分别为 5.2 个月和 12.5 个月。
我们目前的研究表明，Bv 与化疗联合使用可提供高 CRR，从而允许在 R/R PTCL 中进行 SCT。在这种情况下使用 Bv 治疗需要进一步研究。
